{"id":209801,"date":"2010-01-21T18:05:12","date_gmt":"2010-01-21T23:05:12","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=59603"},"modified":"2010-01-21T18:05:12","modified_gmt":"2010-01-21T23:05:12","slug":"somaxon-revises-fda-application","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/209801","title":{"rendered":"Somaxon Revises FDA Application"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/sleep\/\">sleep<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/FDA\/\">FDA<\/a><\/div>\n<p>\t\t<strong>Denise Gellene wrote:<\/strong><\/p>\n<p>San Diego-based Somaxon<a href=\"http:\/\/www.businesswire.com\/portal\/site\/home\/permalink\/?ndmViewId=news_view&amp;newsId=20100121005997&amp;newsLang=en\"> said<\/a> it submitted a revised application for its experimental sleeping pill doxepin (Silenor) to the FDA today, with a decision expected by March 21. The revised application addressed the agency&#8217;s questions about the efficacy of the drug in non-elderly adults, according to a <a href=\"http:\/\/www.somaxon.com\/\">Somaxon<\/a> press release. The FDA has rejected Somaxon&#8217;s application to market doxepin twice.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/21\/somaxon-revises-fda-application\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Somaxon%20Revises%20FDA%20Application%20http:\/\/xconomy.com\/?p=59603\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/san-diego\/2010\/01\/21\/somaxon-revises-fda-application\/&#038;t=Somaxon%20Revises%20FDA%20Application\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/san-diego\/2010\/01\/21\/somaxon-revises-fda-application\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Somaxon+Revises+FDA+Application&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fsan-diego%2F2010%2F01%2F21%2Fsomaxon-revises-fda-application%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=5ff542e0ffcc4c74e1ba6a4885d90c5c&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=5ff542e0ffcc4c74e1ba6a4885d90c5c&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/Kv9WDkK87SOIoC1zJ1Br6xLi5zc\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/Kv9WDkK87SOIoC1zJ1Br6xLi5zc\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/Kv9WDkK87SOIoC1zJ1Br6xLi5zc\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/Kv9WDkK87SOIoC1zJ1Br6xLi5zc\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/LMjaehsSiRc\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, sleep, FDA Denise Gellene wrote: San Diego-based Somaxon said it submitted a revised application for its experimental sleeping pill doxepin (Silenor) to the FDA today, with a decision expected by March 21. The revised application addressed the agency&#8217;s questions about the efficacy of the drug in non-elderly adults, according to a Somaxon press release. [&hellip;]<\/p>\n","protected":false},"author":2918,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-209801","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/209801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2918"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=209801"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/209801\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=209801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=209801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=209801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}